Abstract 537P
Background
Pulmonary metastasectomy is a commonly performed operation, but with inconclusive evidence for effectiveness. The aim of this study is to investigate the patient outcome after pulmonary metastasectomy in sarcoma patients with pulmonary metastases.
Methods
We retrospectively reviewed patients undergoing pulmonary metastasectomy for metastatic soft tissue and bone sarcomas in a single center. Treatment-free interval (TFI) was defined as the duration from the last date of primary tumor treatment to pulmonary metastasectomy. Recurrence-free interval (RFI), defined as the time from pulmonary metastasectomy to identification of new pulmonary metastasis, was calculated to determine freedom from lung recurrence. Post-metastasectomy survival (PMS) was defined as the time from pulmonary metastasectomy to death. Kaplan-Meier plots and Log-rank test were used to identify prognostic factors.
Results
Data of 102 patients were include in the analysis. In the RFI analysis, 77.4% patients (79/102) developed new pulmonary metastasis after pulmonary metastasectomy, with a median duration of 8.9 months. The 2-year freedom from lung recurrence was 23.6% and 51.9% in patients with TFI less than 12 months and TFI more than 12 months, respectively (p = 0.040). In the PMS analysis, the extrathoracic recurrence (p = 0.004) and TFI, but not primary site tumor recurrence, were significant prognostic factors. The 2 and 5-year PMS rates were 68.5% and 38.1%, respectively, in patients in patients with TFI less than 12 months, compared to 80.3% and 67.6%, respectively, in patients with TFI more than 12 months (p = 0.028).
Conclusions
A significant proportion (77.4%) of patients developed lung recurrences after pulmonary metastasectomy for sarcoma. Patients with TFI more than 12 months were associated with higher rate of freedom from lung recurrence and better PMS after pulmonary metastasectomy for sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract